Compare APLT & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APLT | SLRC |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 771.9M |
| IPO Year | 2019 | 2010 |
| Metric | APLT | SLRC |
|---|---|---|
| Price | $0.10 | $15.45 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 7 |
| Target Price | $1.25 | ★ $16.04 |
| AVG Volume (30 Days) | ★ 10.8M | 279.9K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 10.61% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.65 |
| Revenue | $1,000,000.00 | ★ $219,666,000.00 |
| Revenue This Year | $124.18 | N/A |
| Revenue Next Year | $66.67 | N/A |
| P/E Ratio | ★ N/A | $9.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $13.64 |
| 52 Week High | $1.50 | $17.94 |
| Indicator | APLT | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 26.55 | 48.07 |
| Support Level | $0.09 | $15.24 |
| Resistance Level | $0.12 | $15.57 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 8.79 | 37.62 |
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.